Thomas E. Mürdter

The FAP × CD3 bispecific antibody OMTX305 induces T cell–mediated antitumor effects in patient-derived ex vivo models of solid tumors

Julia Thiel, Jan Schlegel, Chunguang Liang, Thomas E. Mürdter et autres

de, es (code pays fourni par la source)

Challenging the control through a single-cell perspective on normal adjacent tissue in colorectal cancer

Patricia Raude, Onur Mert Batmaz, Subhiksha Meenakshi Sundaram, Christina Parpoulas et autres

de (code pays fourni par la source)

Abstract 3400: A 3D bioprinted hydrogel-based tumor model of non-small cell lung cancer for preclinical drug testing

Jan Schlegel, Julia Thiel, Kanstantsin Lashuk, Schueler Julia et autres

de (code pays fourni par la source)

Quantitative analysis of underivatised short-chain fatty acids and simultaneous non-targeted metabolic profiling by ultra-high performance liquid chromatography-mass spectrometry

Sylvia K. Neef, Jeannine Opara, Georg Heinkele, Matthias W. Gross et autres

de, us (code pays fourni par la source)

Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres